1
|
Choudhury A, Ortiz DF, Argueta S, Garofalo K, Lansing JC, Jetley U, Wilkins D, Bosques C, Cochran E, Bhatnagar N, Duffner J, Gupta A, Lee S, Srinivasan K, Parge V, Zouaoui R, Wang J, Manning AM. Abstract 561: Discovery of a potential best-in-class anti-CD38 therapeutic utilizing Fc multimerization. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CD38 targeting antibodies are at different phases of clinical development, with daratumumab already approved as monotherapy and in combination with standards of care in multiple myeloma (MM). Anti-CD38 monoclonal antibodies (mAbs) induce tumor cell depletion in part by Fc-dependent effector mechanisms such as antibody dependent cellular cytotoxicity (ADCC), antibody dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC). However, not all MM patients achieve minimal residual disease (MRD)-negativity and similar clinical response. In addition, some patients on daratumumab develop resistance due to reduced cell surface CD38 and high levels of complement inhibitors (CD55 and CD59). We have leveraged Fc multimerization technology (Ortiz et al Sci Transl Med. 2016; 8: 365) to generate an optimized platform (SIF; selective immunomodulator of Fc receptors) that utilizes the valency effect of Fc multimerization to enhance binding to the Fcγ receptors and complement. We combined the Fab-region of CD38 targeting mAb to SIF platform to generate an anti-CD38 SIFbody to enhance immune and complement mediated cytotoxicity against tumor cells. In several human tumor cell line-based cytotoxic assays using primary human effector cells (NK cells and macrophages) and complement, the anti-CD38 SIFbody demonstrates up to 10-fold increase in efficacy and ≥16-fold increase in potency compared to daratumumab and the surrogate therapeutic anti-CD38 mAb (TAK-079). In isolated whole human blood incubated with tumor cells, the anti-CD38 SIFbody demonstrated 40-100 fold increase in potency and 2-3 fold increase in efficacy. In bone marrow cells isolated from MM patients with >80% plasma cells anti-CD38 SIFbody showed better potency and a 3-5 fold increased efficacy (with 100% plasma cell elimination) than daratumumab, suggesting the SIFbody may be more suitable molecule for achieving greater MRD-negativity rates in MM patients. Daratumumab fails to induce CDC against tumor cell lines with low CD38 and high CD55 and CD59, however the SIFbody achieves 100% efficacy in such settings, suggesting this molecule may be effective in patients who are developing resistance to treatment. In single dose pharmacodynamic and tolerability studies in cynomolgus monkeys SIFbody demonstrated up to 5-fold increase in B cell depletion from peripheral blood compared to TAK-079 across all dose ranges (0.3, 1, & 3 mg/kg) tested without any adverse events. Therefore, by leveraging our Fc multimerization technology we have generated a differentiated potential best-in-class anti-CD38 therapeutic.
Citation Format: Amit Choudhury, Daniel F. Ortiz, Shannon Argueta, Kevin Garofalo, Jonathan C. Lansing, Utsav Jetley, Danice Wilkins, Carlos Bosques, Edward Cochran, Naveen Bhatnagar, Jay Duffner, Abhinav Gupta, Stan Lee, Karunya Srinivasan, Viraj Parge, Radouane Zouaoui, Jason Wang, Anthony M. Manning. Discovery of a potential best-in-class anti-CD38 therapeutic utilizing Fc multimerization [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 561.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Stan Lee
- Momenta Pharmaceuticals, Cambridge, MA
| | | | | | | | | | | |
Collapse
|
2
|
Roy S, Nanovskaya T, Patrikeeva S, Cochran E, Parge V, Guess J, Schaeck J, Choudhury A, Ahmed M, Ling LE. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model. Am J Obstet Gynecol 2019; 220:498.e1-498.e9. [PMID: 30849355 DOI: 10.1016/j.ajog.2019.02.058] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2018] [Revised: 02/22/2019] [Accepted: 02/27/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND The transfer of pathogenic immunoglobulin G antibodies from mother to fetus is a critical step in the pathophysiology of alloimmune and autoimmune diseases of the fetus and neonate. Immunoglobulin G transfer across the human placenta to the fetus is mediated by the neonatal Fc receptor, and blockade of the neonatal Fc receptor may provide a therapeutic strategy to prevent or minimize pathological events associated with immune-mediated diseases of pregnancy. M281 is a fully human, aglycosylated monoclonal immunoglobulin G1 antineonatal Fc receptor antibody that has been shown to block the neonatal Fc receptor with high affinity in nonclinical studies and in a phase 1 study in healthy volunteers. OBJECTIVE The objective of the study was to determine the transplacental transfer of M281 and its potential to inhibit transfer of immunoglobulin G from maternal to fetal circulation. STUDY DESIGN To determine the concentration of M281 required for rapid cellular uptake and complete saturation of the neonatal Fc receptor in placental trophoblasts, primary human villous trophoblasts were incubated with various concentrations of M281 in a receptor occupancy assay. The placental transfer of M281, immunoglobulin G, and immunoglobulin G in the presence of M281 was studied using the dually perfused human placental lobule model. Immunoglobulin G transfer was established using a representative immunoglobulin G molecule, adalimumab, a human immunoglobulin G1 monoclonal antibody, at a concentration of 270 μg/mL. Inhibition of immunoglobulin G transfer by M281 was determined by cotransfusing 270 μg/mL of adalimumab with 10 μg/mL or 300 μg/mL of M281. Concentrations of adalimumab and M281 in sample aliquots from maternal and fetal circuits were analyzed using a sandwich enzyme-linked immunosorbent assay and Meso Scale Discovery assay, respectively. RESULTS In primary human villous trophoblasts, the saturation of the neonatal Fc receptor by M281 was observed within 30-60 minutes at 0.15-5.0 μg/mL, suggesting rapid blockade of neonatal Fc receptor in placental cells. The transfer rate of adalimumab (0.23% ± 0.21%) across dually perfused human placental lobule was significantly decreased by 10 μg/mL and 300 μg/mL of M281 to 0.07 ± 0.01% and 0.06 ± 0.01%, respectively. Furthermore, the transfer rate of M281 was 0.002% ± 0.02%, approximately 100-fold lower than that of adalimumab. CONCLUSION The significant inhibition of immunoglobulin G transfer across the human placental lobule by M281 and the minimal transfer of M281 supports the development of M281 as a novel agent for the treatment of fetal and neonatal diseases caused by transplacental transfer of alloimmune and autoimmune pathogenic immunoglobulin G antibodies.
Collapse
|
3
|
Chopda GR, Parge V, Thakur GA, Gatley SJ, Makriyannis A, Paronis CA. Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice. J Pharmacol Exp Ther 2016; 358:334-41. [PMID: 27231154 DOI: 10.1124/jpet.116.232132] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Accepted: 05/23/2016] [Indexed: 01/15/2023] Open
Abstract
Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ-opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the Bmax value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function.
Collapse
Affiliation(s)
- Girish R Chopda
- Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
| | - Viraj Parge
- Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
| | - Ganesh A Thakur
- Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
| | - S John Gatley
- Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
| | - Alexandros Makriyannis
- Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
| | - Carol A Paronis
- Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.)
| |
Collapse
|
4
|
Ling L, Roy S, Meador J, Kehry M, Mekala D, Tyler S, Bulik D, Choudhury A, Markowitz L, Schultes B, Avery W, Parge V, Cochran E, King D, Kaundinya G, Manning A. THU0057 Targeting the Neonatal FC Receptor (FCRN) to Mediate Autoantibody Clearance in IgG-Driven Autoimmune Disease. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|